NCT06284746 - Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

July 30, 2025

Conditions

Locally Advanced Gastric CarcinomaHER2 NegativeEfficacySafety

Interventions

DRUG

Tirolizumab+SOX/XELOX

Tirolizumab combined with chemotherapy(SOX/XELOX) regimen. The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.

DRUG

SOX/XELOX

Simple chemotherapy regimen (SOX/XELOX regimen). The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.

Trial Locations (1)

100853

RECRUITING

General Surgery Institute, China PLA General Hospital, Beijing